Fitxers

684287.pdf (1.39 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-01-08

Llicència de publicació

cc-by (c) Gratacós, Jordi et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/128157

Non-inferiority of dose reduction versusstandard dosing of TNF-inhibitors in axial spondyloarthritis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s13075-018-1772-z

Resum

Objective: the objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis. Methods: randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients were eligible if they had axial spondyloarthritis and had been in clinical remission for ≥ 6 months with any available TNFi (adalimumab, etanercept, infliximab, golimumab) at the dose recommended by product labelling. Patients were randomized by automated central allocation to continue the same TNFi dose schedule, or to reduce the dose by roughly half according to the protocol. The main outcome was the proportion of subjects with LDA after 1 year. Serious adverse reactions or infections were recorded. Results: the trial stopped due to end of the funding period, after 126 patients were randomized; 113 patients (84.1% male, mean age (SD) 45.6 (13.0) years) were included in the main per-protocol subset. Non-inferiority was concluded for LDA at 1 year (47/55 (83.8%) patients in the full-dose and 48/58 (81.3%) patients in the reduced-dose arm, adjusted difference (95% CI) − 2.5% (− 16.6% to 11.7%)). Serious adverse reactions or infections were reported in 7/62 patients (11.3%) assigned to full dose and 2/61 patients (3.3%) assigned to reduced dose (p value = 0.164). Conclusion: in patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses.

Matèries

Espondiloartropaties, Administració de medicaments, Posologia, Citoquines

Matèries (anglès)

Spondyloarthropathies, Administration of drugs, Posology, Cytokines

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Citació

GRATACÓS MASMITJÀ, Jordi, et al. Non-inferiority of dose reduction versusstandard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Research & Therapy. 2019. Vol. 21, núm. 11. ISSN 1478-6362. [consulta: 10 de maig de 2026]. Disponible a: https://hdl.handle.net/2445/128157

Exportar metadades

JSON - METS

Compartir registre